Nate's note靠谱吗？在推荐这只垃圾股# Stock
w*a
1 楼
Top Picks Update
MannKind (MNKD 1.32)
From Nate’s Notes
Though shares of MannKind (MNKD) have continued to struggle following a
reverse split that was carried out back in March, the company's lead
product, Afrezza (an inhaled form of insulin for both Type-1 and Type-2
diabetics) is continuing to win high praises and gain converts among the
small number of patients who have actually heard about it so far.
Up until this point, the company has done virtually no advertising of the
product, but this is about to change—thanks to not only the sponsorship of
a "reality" TV show (called Reversed) focused on T2 diabetics that
is scheduled to air this month—but also due to the much-anticipated launch
of an actual TV commercial and advertising campaign for Afrezza.
In addition, the company has filed for a label change on the product that
should help drum up additional interest, with the improved label anticipated
to be approved by the FDA sometime late in the third quarter.
The company's Board has also made some significant changes in top
management over the past couple of months, including replacing the CEO.
Close to a third of the float of the stock is still sold short on what I
believe is a misinformed premise about the efficacy of the drug, and as time
goes by, the repurchase of these shares ought to help accelerate the return
of the stock to a more realistic valuation. MNKD remains a strong buy under
$5 and a buy under $10.
Nate Pile, Nate’s Notes, www.NotWallStreet.com, 707-433-7903, July 14, 2017
MannKind (MNKD 1.32)
From Nate’s Notes
Though shares of MannKind (MNKD) have continued to struggle following a
reverse split that was carried out back in March, the company's lead
product, Afrezza (an inhaled form of insulin for both Type-1 and Type-2
diabetics) is continuing to win high praises and gain converts among the
small number of patients who have actually heard about it so far.
Up until this point, the company has done virtually no advertising of the
product, but this is about to change—thanks to not only the sponsorship of
a "reality" TV show (called Reversed) focused on T2 diabetics that
is scheduled to air this month—but also due to the much-anticipated launch
of an actual TV commercial and advertising campaign for Afrezza.
In addition, the company has filed for a label change on the product that
should help drum up additional interest, with the improved label anticipated
to be approved by the FDA sometime late in the third quarter.
The company's Board has also made some significant changes in top
management over the past couple of months, including replacing the CEO.
Close to a third of the float of the stock is still sold short on what I
believe is a misinformed premise about the efficacy of the drug, and as time
goes by, the repurchase of these shares ought to help accelerate the return
of the stock to a more realistic valuation. MNKD remains a strong buy under
$5 and a buy under $10.
Nate Pile, Nate’s Notes, www.NotWallStreet.com, 707-433-7903, July 14, 2017